Tylosin (Tylan)

Tylosin, marketed under the brand name Tylan, is one of the oldest and most versatile macrolide antibiotics in food animal medicine, with a history of use spanning more than five decades. Originally derived from Streptomyces fradiae, tylosin has maintained its place in veterinary therapeutics due to its broad spectrum of activity, multiple formulation options, and established safety profile across numerous food animal species. The drug is available in injectable, water-soluble, and feed-additive formulations, providing flexibility to address diverse clinical needs and production system requirements.

The mechanism of action of tylosin, like other macrolide antibiotics, involves binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the host immune system to clear the infection. Tylosin demonstrates activity against many gram-positive bacteria, certain gram-negative organisms, Mycoplasma species, and some spirochetes. Its spectrum of activity has made it particularly valuable for conditions where these pathogens are implicated, including respiratory infections, enteric diseases, and liver abscesses in cattle.

Tylosin is available in multiple formulations designed for different routes of administration and production applications. Injectable formulations include Tylan 50 (50 mg/mL) and Tylan 200 (200 mg/mL) for intramuscular administration. Tylan Soluble is a water-soluble powder for oral administration via drinking water, particularly useful in poultry and swine operations. Tylan Premix is a Type A medicated article for incorporation into feed, used for continuous medication of cattle, swine, and poultry. This range of formulations allows tylosin to be administered by the most appropriate route for each clinical situation and production system.

The regulatory status of tylosin varies by formulation and intended use. Injectable products require veterinary prescription. Feed-use products are subject to Veterinary Feed Directive (VFD) requirements, meaning they require authorization from a licensed veterinarian within the context of a valid veterinarian-client-patient relationship. Some water-soluble products may have over-the-counter status for certain species and uses. Understanding the regulatory requirements for each formulation is essential for legal compliance. Tylosin is approved for use in multiple species including cattle, swine, poultry, and sheep, making it one of the more broadly applicable macrolides in food animal medicine.

One of the most significant applications of tylosin in modern cattle production is the prevention and control of liver abscesses in feedlot cattle. Liver abscesses, caused primarily by Fusobacterium necrophorum and Trueperella pyogenes following ruminal acidosis and rumenitis, represent a major economic concern in intensive beef production. When incorporated into feed at approved dosages, tylosin reduces the incidence of liver abscesses at slaughter, improving both animal welfare and carcass value. This use accounts for a substantial proportion of total tylosin consumption in the United States cattle industry and has been standard practice in feedlot operations for decades.

In cattle, tylosin is also indicated for the treatment of bovine respiratory disease (BRD) caused by susceptible organisms, including Pasteurella multocida and Mannheimia haemolytica. While newer macrolides with single-dose protocols have largely supplanted tylosin for acute BRD treatment in feedlot settings, tylosin remains a valuable option, particularly in cow-calf operations or situations where its specific activity spectrum or formulation options are advantageous. The injectable formulation provides flexibility for individual animal treatment when parenteral therapy is indicated.

Swine applications for tylosin include treatment and control of swine dysentery caused by Brachyspira hyodysenteriae, a severe and economically important enteric disease. Tylosin's activity against this spirochete makes it a key tool in swine dysentery control programs. Additionally, tylosin is used for treatment and control of proliferative enteropathies and other enteric infections in swine. The water-soluble and feed-additive formulations facilitate mass medication approaches appropriate for herd-level disease management in commercial swine production.

Poultry applications for tylosin focus on chronic respiratory disease (CRD) caused by Mycoplasma gallisepticum and infectious sinusitis. Mycoplasma infections in poultry cause significant production losses through reduced growth, decreased egg production, and increased susceptibility to secondary infections. Tylosin's activity against Mycoplasma species makes it valuable for both treatment and control of these conditions. Administration via drinking water allows efficient medication of entire flocks, which is essential in modern poultry production systems where individual bird treatment is impractical.

Additional approved uses across species include treatment of metritis in cattle, erysipelas in swine, and various other infections caused by tylosin-susceptible organisms. The breadth of approved indications reflects tylosin's decades-long presence in food animal medicine and its established efficacy against a range of important pathogens. For any specific use, consultation with product labeling and veterinary guidance ensures that applications are consistent with current approvals and recommended practices.

Injectable tylosin dosing in cattle for treatment of respiratory disease and other acute infections is typically 8 to 10 mg per kilogram of body weight (8-10 mg/kg) administered intramuscularly. Using Tylan 200 (200 mg/mL), this equates to approximately 4 to 5 mL per 100 kilograms of body weight. Treatment is usually continued for 3 to 5 days, with injections given once or twice daily depending on the severity of infection and prescribing veterinarian's recommendations. The intramuscular route is the only approved route for injectable tylosin; subcutaneous injection is not recommended and may result in variable absorption and local tissue reactions.

For liver abscess control in feedlot cattle, tylosin is administered continuously in the feed at levels of 60 to 90 mg per head per day, depending on the specific product label and animal weight. This continuous low-level administration maintains tissue concentrations adequate to suppress the organisms responsible for abscess formation without necessarily eliminating them entirely. The duration of feeding typically extends throughout the finishing period, from arrival through slaughter. Proper feed mixing to ensure uniform drug distribution is essential for consistent dosing across all animals in the group.

Swine dosing varies by indication and route of administration. For treatment of swine dysentery via drinking water, tylosin is typically administered at a concentration of 0.025% (250 mg/L) for 3 to 10 days. Feed medication for various swine conditions uses tylosin phosphate at levels ranging from 20 to 100 grams per ton of feed depending on the indication and duration of treatment. Injectable tylosin in swine follows similar mg/kg dosing as in cattle, with treatment duration adjusted to clinical response. The specific product label provides detailed dosing guidance for each approved indication.

Poultry administration is typically via drinking water at concentrations ranging from 500 to 1000 mg per gallon (0.5 to 1.0 g/L) for 5 to 7 days for treatment of chronic respiratory disease. Feed medication is used for control programs at various levels depending on the specific product and indication. Given that poultry are typically managed as flocks rather than individuals, water and feed medication routes are far more practical than injectable treatment. Proper calculation of water consumption and feed intake ensures that intended doses are actually received by the birds.

Withdrawal times for tylosin vary by species, formulation, and route of administration, making careful attention to specific product labeling essential. For cattle receiving injectable tylosin, the meat withdrawal period is typically 21 days. For cattle receiving tylosin in feed for liver abscess control, there is typically no withdrawal period at approved use levels, but this must be verified against the specific product label. Swine withdrawal periods vary from 2 to 14 days depending on formulation and use level. Poultry withdrawal periods similarly vary by product and use. For any species and formulation, the specific product label provides the authoritative withdrawal time that must be observed. Tylosin is not approved for use in lactating dairy cattle producing milk for human consumption.

Tylosin has a long-established safety profile in food animals, with adverse effects being relatively uncommon when the drug is used according to label directions. The most frequently observed side effects with injectable formulations are injection site reactions, a common occurrence with intramuscular administration of any drug. These reactions may include transient swelling, firmness, and discomfort at the injection site. The severity of injection site reactions can be influenced by the formulation concentration, injection volume, injection technique, and individual animal factors. Proper injection technique and appropriate needle selection help minimize local tissue reactions.

Injection site lesions may persist in some animals and have implications for carcass quality at slaughter. Intramuscular injection can result in muscle damage and scarring that requires trimming during processing. For this reason, injection in the neck region is preferred to avoid lesions in high-value carcass areas. Even with proper technique, some residual lesion formation is expected with intramuscular injection. The economic impact of injection site lesions has driven preferences toward subcutaneous administration routes for many newer antibiotics, though tylosin's approved route remains intramuscular.

Gastrointestinal effects are possible with oral tylosin administration, as with any antimicrobial that affects gut flora. Alterations in the intestinal microbiome may result in changes in fecal consistency or, less commonly, more significant digestive disturbances. These effects are generally mild and self-limiting, resolving after completion of the treatment course. In ruminants receiving tylosin in feed for liver abscess prevention, effects on ruminal flora are minimal at approved use levels, though disruption of normal rumen function is theoretically possible with excessive dosing.

Systemic adverse effects following tylosin administration are uncommon but may include transient decreases in feed intake, lethargy, or mild signs of gastrointestinal discomfort. These effects are typically mild and resolve without specific treatment. Unlike some other macrolides that have significant cardiovascular toxicity in certain species, tylosin has not been associated with serious cardiac effects in food animals at recommended doses. The drug has been used safely in cattle, swine, and poultry for decades without significant cardiac safety concerns emerging.

Hypersensitivity reactions are possible with any drug but are not a prominent feature of tylosin's adverse effect profile. Animals with previous adverse reactions to tylosin or other macrolides should be carefully evaluated before retreatment. Any signs of allergic response, including swelling, respiratory distress, or skin reactions, should prompt discontinuation of treatment and veterinary evaluation.

Tylosin is contraindicated in animals with known hypersensitivity to the drug or to other macrolide antibiotics. While hypersensitivity reactions to tylosin are uncommon, animals that have experienced allergic or adverse responses to tylosin or structurally related compounds should not receive the drug. Cross-reactivity between macrolide antibiotics is possible, and animals with documented reactions to other macrolides such as tilmicosin, tulathromycin, or erythromycin should be carefully evaluated before tylosin administration.

Tylosin is not approved for use in lactating dairy cattle producing milk for human consumption. This restriction reflects the lack of an established milk withdrawal time and the potential for drug residues in milk. Dairy operations must ensure that tylosin is not administered to cattle in the milking herd. Any inadvertent treatment of lactating dairy cattle requires milk withholding according to regulatory guidance and consultation with a veterinarian to establish appropriate withholding periods based on available pharmacokinetic data.

Species-specific restrictions apply to tylosin use in horses. While tylosin is not associated with the acute fatal cardiovascular toxicity seen with some other macrolides in horses, its use in equines is generally not recommended. Horses have developed serious and sometimes fatal colitis following macrolide antibiotic administration, likely due to disruption of normal intestinal flora and overgrowth of pathogenic organisms. This risk applies to macrolides as a class, and tylosin should not be administered to horses except under specific veterinary guidance with full understanding of the potential consequences.

Layer chickens producing eggs for human consumption have specific restrictions depending on the tylosin formulation and regulatory jurisdiction. The presence of residues in eggs is a food safety concern, and some tylosin products are not approved for use in laying hens. Producers must verify that any tylosin product used in poultry is approved for the specific production class and that any egg withdrawal requirements are followed. The regulatory requirements for medicated feeds and water medications in poultry are complex and require careful attention to labeling and VFD requirements.

Drug interactions with tylosin include considerations common to macrolide antibiotics as a class. Concurrent administration of multiple macrolide antibiotics should be avoided because this provides no additional therapeutic benefit while potentially increasing the risk of adverse effects and promoting resistance selection. Animals receiving tylosin should not simultaneously receive other macrolides such as tilmicosin, tulathromycin, tildipirosin, or gamithromycin. Sequential use of different macrolides within a short timeframe should also be carefully evaluated.

The interaction between macrolide antibiotics and ionophore feed additives warrants consideration in cattle operations. Ionophores including monensin, lasalocid, and laidlomycin are commonly incorporated into cattle feeds. While tylosin has been used concurrently with ionophores in feedlot cattle for decades without prominent interaction concerns emerging, the potential for interaction exists with macrolides as a class. The extensive field use of tylosin with ionophores provides some reassurance, but any unusual adverse effects in cattle receiving both should prompt veterinary evaluation.

Potential antagonism between bacteriostatic and bactericidal antimicrobials applies to tylosin. As a macrolide, tylosin is bacteriostatic, inhibiting bacterial growth rather than directly killing organisms. Combination with bactericidal antibiotics could theoretically reduce the efficacy of the bactericidal agent, which typically requires actively dividing bacteria for optimal effect. The clinical significance of this potential interaction varies by pathogen and clinical situation, and veterinary guidance should inform decisions about combination antimicrobial therapy.

In poultry, potential interactions between tylosin and other medications commonly used in flock management should be considered. Many poultry operations use multiple medications including coccidiostats, other antibiotics, and various feed additives. While specific interaction data for all possible combinations with tylosin are limited, awareness of the potential for interactions is appropriate. The simultaneous use of multiple antimicrobials should be based on specific therapeutic indications and veterinary guidance rather than routine practice. Particular attention should be paid to any medications with known macrolide interactions when planning treatment protocols.

Human safety precautions apply to the handling of tylosin products. Direct contact with tylosin may cause skin sensitization and allergic reactions in susceptible individuals. Handlers should wear appropriate personal protective equipment, including gloves and eye protection, during product handling and administration. Persons with known hypersensitivity to macrolide antibiotics should avoid direct contact with tylosin products. In the event of accidental skin contact, the affected area should be washed with soap and water. Eye exposure should be managed by flushing with water for at least 15 minutes, and medical attention should be sought if irritation persists.

Accidental self-injection with injectable tylosin formulations should prompt medical attention. While tylosin does not carry the same level of acute toxicity concern as some other veterinary injectables, local tissue reaction and potential systemic effects warrant evaluation. Healthcare providers should be informed that the product is a macrolide antibiotic used in veterinary medicine. Persons with known sensitivity to macrolide antibiotics should exercise particular care to avoid exposure and should seek medical attention promptly if exposure occurs.

Food safety and residue avoidance require strict adherence to withdrawal times specific to each species, formulation, and use. The variability in withdrawal requirements across tylosin products makes careful attention to specific product labeling essential. Animals should not be slaughtered for food until the appropriate withdrawal period has elapsed. Eggs from treated laying hens (where use is permitted) may require withholding depending on the specific product and jurisdiction. Proper identification of treated animals and groups, accurate record-keeping, and clear communication between treatment and marketing personnel are essential for residue prevention.

Antimicrobial stewardship principles require judicious use of tylosin to preserve its efficacy for future needs. The drug should be used only when indicated for specific therapeutic or preventive purposes according to approved labeling or valid veterinary prescription. The long-standing use of tylosin in food animal production has inevitably contributed to selection pressure on bacterial populations, and responsible use practices help minimize additional resistance development. Treatment decisions should be made in consultation with veterinarians as part of comprehensive health management programs that incorporate prevention, biosecurity, and non-antimicrobial interventions alongside judicious antimicrobial use.

Veterinary Feed Directive requirements apply to feed-use tylosin products. Under current regulations, medicated feeds containing tylosin require authorization from a licensed veterinarian within the context of a valid VCPR. The VFD must specify the client, animals to be treated, indication, duration of use, and other required information. Feed mills must maintain VFD records, and producers must retain copies. These regulatory requirements are designed to ensure veterinary oversight of antimicrobial use in feed and do not apply to non-feed formulations, which have their own regulatory frameworks.

Injectable tylosin formulations should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with brief excursions permitted between 15°C and 30°C (59°F to 86°F). Products should be protected from direct light and from freezing. In farm settings where temperature control may be challenging, storage in climate-controlled areas helps maintain product integrity. Once opened, multi-dose vials should be used within a reasonable timeframe, typically 28 days unless otherwise specified on the product label. Visual inspection before use helps identify any product changes that might indicate deterioration.

Water-soluble tylosin products should be stored in a cool, dry place protected from moisture. Exposure to humidity can cause caking or degradation of the powder. Once dissolved for administration, water solutions should be used promptly according to label directions. Medicated water systems should be cleaned between treatment periods to prevent residual contamination. The stability of tylosin solutions varies with concentration, temperature, and water quality, making attention to label directions for solution preparation and use important.

Feed-grade tylosin products (Type A medicated articles) require storage conditions that protect against moisture, contamination, and degradation. The products should be stored in their original sealed containers until ready for use. Proper inventory management ensures that products are used before expiration dates and that older stock is used first. Feed mixing procedures must ensure uniform distribution of the drug throughout the feed batch, as inconsistent mixing results in variable dosing across animals in the feeding group.

Disposal of tylosin products and containers should comply with federal, state, and local regulations. Empty containers should be disposed of according to label directions, which may include triple-rinsing before disposal. Unused or expired product should not be disposed of through regular trash collection or wastewater systems. Pharmaceutical take-back programs or approved disposal facilities may be available for veterinary medications. Sharps used with injectable products should be placed in approved puncture-resistant containers and managed as regulated medical waste. Responsible disposal prevents environmental contamination and reduces the risk of unintended exposure.

Tylosin dosing is consistent across breeds within each species, with weight-based dosing for injectable products and consumption-based dosing for feed and water medications. In cattle, whether treating British, Continental, or dairy breeds, the same mg/kg recommendations apply for injectable tylosin, and the same mg/head/day rates apply for feed-based liver abscess prevention. The extensive history of tylosin use across the cattle industry has not revealed breed-specific dosing requirements, though accurate weight determination remains essential for proper dosing regardless of breed.

Breed-related differences in production systems may influence patterns of tylosin use without changing dosing recommendations. British and British-cross cattle are common in traditional feedlot populations where tylosin is used for liver abscess control. Continental breeds and crosses are similarly represented. Dairy breeds and dairy-beef crosses entering beef production systems have become increasingly common and are managed similarly with respect to tylosin use. The decision to use tylosin in feed for liver abscess prevention is based on production system characteristics (feedlot finishing with high-concentrate diets) rather than breed per se.

In swine, commercial operations use various genetic lines selected for growth, efficiency, and meat quality characteristics. Tylosin use for swine dysentery or other enteric conditions applies across genetic backgrounds without breed-specific considerations. The disease conditions for which tylosin is indicated in swine occur across breed types, and treatment protocols do not differ based on genetics. Accurate weight estimation for individually treated animals and proper feed or water medication calculations for group treatments are more important than breed identity.

Poultry breeds and genetic lines are highly specialized within the commercial poultry industry, with different genetics used for broiler production, egg production, and turkey production. Tylosin approvals and use patterns vary across these production types and species. Broiler operations may use tylosin differently than layer operations (with different regulatory constraints on layer use). Turkey dosing may differ from chicken dosing. Production class (broiler, layer, breeder) is more relevant than breed per se, and attention to species-specific and production class-specific labeling ensures appropriate use across the diversity of commercial poultry production.

Within the macrolide antibiotic class, several alternatives to tylosin are available, each with distinct characteristics that may influence selection for specific indications. Tulathromycin (Draxxin) offers single-dose treatment convenience for acute respiratory disease in cattle and swine, with extended tissue persistence that eliminates the need for multi-day treatment regimens. Gamithromycin (Zactran) similarly provides single-dose efficacy for bovine respiratory disease. Tildipirosin (Zuprevo) is approved for both cattle and swine respiratory disease with comparable convenience. Tilmicosin (Micotil) is effective in cattle but carries critical warnings about fatal toxicity in swine and horses that limit its utility compared to tylosin's broader species applicability.

For liver abscess prevention in feedlot cattle, tylosin has few direct alternatives within the macrolide class. The unique role of tylosin in this application reflects its established efficacy against the causative organisms, its safety profile with continuous feeding, and the regulatory framework that has developed around its use. Other approved feed-additive antimicrobials may address different aspects of feedlot health management but do not necessarily provide equivalent liver abscess efficacy. Discussions about reducing antimicrobial use in livestock production often focus on this application of tylosin given the volume involved.

For swine dysentery, alternatives to tylosin include other antimicrobials with activity against Brachyspira hyodysenteriae. Carbadox has been used for this indication, though regulatory concerns have affected its availability. Lincomycin represents another option for swine enteric disease. Tiamulin, a pleuromutilin antibiotic, has activity against Brachyspira species. The selection among these options depends on regional pathogen susceptibility patterns, regulatory status, withdrawal time requirements, and operational factors. Veterinary guidance helps optimize treatment selection for swine enteric disease.

For poultry respiratory disease, tylosin competes with other antimicrobials effective against Mycoplasma species. Chlortetracycline and other tetracyclines have activity against Mycoplasma. Newer macrolides may offer alternative options in some markets. Non-antimicrobial approaches including vaccination against Mycoplasma gallisepticum and improved biosecurity represent complementary strategies for respiratory disease management in poultry. The overall approach to poultry respiratory disease typically combines antimicrobial treatment for acute disease with vaccination and management practices for long-term control.